Background Serelaxin, recombinant human relaxin-2, is a vasoactive peptide hormone with
many biological and haemodynamic effects. In a pilot study, serelaxin was safe and well …

Background Most patients admitted for acute heart failure have normal or increase blood
pressure. Relaxin is a natural human peptide that affects multiple vascular control pathways, …

Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to
improve cardiac function in patients with heart failure with a reduced ejection fraction. Its …

Background Decreased systolic function is central to the pathogenesis of heart failure in
millions of patients worldwide, but mechanism-related adverse effects restrict existing inotropic …

Background Impaired contractility is a feature of heart failure with reduced ejection fraction.
We assessed the pharmacokinetics and effects on cardiac function and structure of the …

The purpose of the present study was to gain a better understanding of the relation between
ventricular remodeling and heart failure by assessing the adaptation of the heart through …

The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular
death or heart failure hospitalization in patients with chronic heart failure, but whether …

Background—Ventricular arrhythmias are a frequent finding in congestive heart failure (CHF)
patients and a cause of concern for physicians caring for them. Previous studies have …

Background Nesiritide is approved in the United States for early relief of dyspnea in patients
with acute heart failure. Previous meta-analyses have raised questions regarding renal …

of Key Points In this document, we propose a universal definition of heart failure (HF) as the
following: HF is a clinical syndrome with symptoms and or signs caused by a structural and/…